Literature DB >> 19896098

Desmoplasia of pancreatic ductal adenocarcinoma.

Stephen Pandol1, Mouad Edderkaoui, Ilya Gukovsky, Aurelia Lugea, Anna Gukovskaya.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer and is characterized by remarkable desmoplasia. The desmoplasia is composed of extracellular matrix (ECM) proteins, myofibroblastic pancreatic stellate cells, and immune cells associated with a multitude of cytokines, growth factors, and ECM metabolizing enzymes. The mechanisms of participation of this complex matrix process in carcinogenesis are only starting to be appreciated. Recent studies showed key roles for stellate cells in the production of ECM proteins as well as cytokines and growth factors that promote the growth of the cancer cells all present in the desmoplastic parts of PDAC. In addition, interactions of ECM proteins and desmoplastic secreted growth factors with the cancer cells of PDAC activate intracellular signals including reactive oxygen species that act to make the cancer cells resistant to dying. These findings suggest that the desmoplasia of PDAC is a key factor in regulating carcinogenesis of PDAC as well as responses to therapies. A better understanding of the biology of desmoplasia in the mechanism of PDAC will likely provide significant opportunities for better treatments for this devastating cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896098      PMCID: PMC4573641          DOI: 10.1016/j.cgh.2009.07.039

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  32 in total

1.  Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma.

Authors:  Thomas Armstrong; Graham Packham; Lindsay B Murphy; Adrian C Bateman; John A Conti; David R Fine; Colin D Johnson; R Christopher Benyon; John P Iredale
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

Review 2.  The pancreatic stellate cell: a star on the rise in pancreatic diseases.

Authors:  M Bishr Omary; Aurelia Lugea; Anson W Lowe; Stephen J Pandol
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma.

Authors:  H Yamamoto; F Itoh; Y Adachi; H Sakamoto; M Adachi; Y Hinoda; K Imai
Journal:  Gastroenterology       Date:  1997-04       Impact factor: 22.682

4.  High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.

Authors:  Friedrich H Schmitz-Winnenthal; Christine Volk; Kaspar Z'graggen; Luis Galindo; Daniel Nummer; Yvonne Ziouta; Marianna Bucur; Jürgen Weitz; Volker Schirrmacher; Markus W Büchler; Philipp Beckhove
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

5.  Extracellular matrix proteins protect pancreatic cancer cells from death via mitochondrial and nonmitochondrial pathways.

Authors:  Eva C Vaquero; Mouad Edderkaoui; Kyung J Nam; Ilya Gukovsky; Stephen J Pandol; Anna S Gukovskaya
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

6.  Pancreatic tumor cells influence the composition of the extracellular matrix.

Authors:  Jörg Köninger; Thomas Giese; Fabio F di Mola; Moritz N Wente; Irene Esposito; Max G Bachem; Nathalia A Giese; Markus W Büchler; Helmut Friess
Journal:  Biochem Biophys Res Commun       Date:  2004-09-24       Impact factor: 3.575

7.  Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro.

Authors:  J Mollenhauer; I Roether; H F Kern
Journal:  Pancreas       Date:  1987       Impact factor: 3.327

Review 8.  Epidemiology and risk factors in pancreatic cancer.

Authors:  J D Ahlgren
Journal:  Semin Oncol       Date:  1996-04       Impact factor: 4.929

9.  Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis.

Authors:  T Imamura; H Iguchi; T Manabe; G Ohshio; T Yoshimura; Z H Wang; H Suwa; S Ishigami; M Imamura
Journal:  Pancreas       Date:  1995-11       Impact factor: 3.327

Review 10.  Pancreatic cancer microenvironment.

Authors:  Jörg Kleeff; Philipp Beckhove; Irene Esposito; Stephan Herzig; Peter E Huber; J Matthias Löhr; Helmut Friess
Journal:  Int J Cancer       Date:  2007-08-15       Impact factor: 7.396

View more
  91 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Identification and manipulation of biliary metaplasia in pancreatic tumors.

Authors:  Kathleen E Delgiorno; Jason C Hall; Kenneth K Takeuchi; Fong Cheng Pan; Christopher J Halbrook; M Kay Washington; Kenneth P Olive; Jason R Spence; Bence Sipos; Christopher V E Wright; James M Wells; Howard C Crawford
Journal:  Gastroenterology       Date:  2013-08-30       Impact factor: 22.682

3.  Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1.

Authors:  George S Karagiannis; Aaron Berk; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2013-04-18       Impact factor: 6.603

4.  Ellagic acid and embelin affect key cellular components of pancreatic adenocarcinoma, cancer, and stellate cells.

Authors:  Mouad Edderkaoui; Aurelia Lugea; Hongxiang Hui; Guido Eibl; Qing-Yi Lu; Aune Moro; Xuyang Lu; Gang Li; Vay-Liang Go; Stephen J Pandol
Journal:  Nutr Cancer       Date:  2013-10-15       Impact factor: 2.900

5.  Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance.

Authors:  Min Shi; Dang-Hui Yu; Ying Chen; Chen-Yan Zhao; Jing Zhang; Qing-Hua Liu; Can-Rong Ni; Ming-Hua Zhu
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

Review 6.  Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Wanxing Duan; Jianjun Lei; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.

Authors:  Edward J Kim; Vaibhav Sahai; Ethan V Abel; Kent A Griffith; Joel K Greenson; Naoko Takebe; Gazala N Khan; John L Blau; Ronald Craig; Ulysses G Balis; Mark M Zalupski; Diane M Simeone
Journal:  Clin Cancer Res       Date:  2014-10-02       Impact factor: 12.531

8.  Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma.

Authors:  Dirk Bausch; Thomas Pausch; Tobias Krauss; Ulrich Theodor Hopt; Carlos Fernandez-del-Castillo; Andrew L Warshaw; Sarah P Thayer; Tobias Keck
Journal:  Angiogenesis       Date:  2011-03-26       Impact factor: 9.596

9.  A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Authors:  Bridget P Keenan; Yvonne Saenger; Michel I Kafrouni; Ashley Leubner; Peter Lauer; Anirban Maitra; Agnieszka A Rucki; Andrew J Gunderson; Lisa M Coussens; Dirk G Brockstedt; Thomas W Dubensky; Raffit Hassan; Todd D Armstrong; Elizabeth M Jaffee
Journal:  Gastroenterology       Date:  2014-03-06       Impact factor: 22.682

Review 10.  Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.

Authors:  Chiara Birtolo; Vay Liang W Go; Andrzej Ptasznik; Guido Eibl; Stephen J Pandol
Journal:  Pancreas       Date:  2016-01       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.